Globus Medical, Inc. (NYSE:GMED) Sees Large Decrease in Short Interest

Globus Medical, Inc. (NYSE:GMED) was the target of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 3,270,517 shares, a decrease of 30.1% from the February 12th total of 4,675,619 shares. Approximately 3.0% of the company’s stock are sold short. Based on an average daily trading volume, of 1,421,356 shares, the days-to-cover ratio is currently 2.3 days. Based on an average daily trading volume, of 1,421,356 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.0% of the company’s stock are sold short.

Globus Medical Stock Up 0.4%

Shares of GMED traded up $0.30 during mid-day trading on Friday, reaching $84.81. The company had a trading volume of 1,252,169 shares, compared to its average volume of 1,114,077. The stock has a market capitalization of $11.47 billion, a P/E ratio of 21.52, a PEG ratio of 1.99 and a beta of 1.05. Globus Medical has a 52-week low of $51.79 and a 52-week high of $101.40. The stock has a 50 day moving average of $90.71 and a two-hundred day moving average of $78.37.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The company had revenue of $826.42 million during the quarter, compared to analysts’ expectations of $803.29 million. During the same period last year, the business earned $0.84 earnings per share. Globus Medical’s quarterly revenue was up 25.7% on a year-over-year basis. On average, sell-side analysts expect that Globus Medical will post 3.44 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on GMED shares. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Citigroup restated a “market perform” rating on shares of Globus Medical in a research note on Thursday, January 8th. Needham & Company LLC lifted their price objective on shares of Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group lifted their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Finally, Truist Financial set a $115.00 target price on Globus Medical in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Insider Buying and Selling

In other Globus Medical news, Director Leslie V. Norwalk sold 2,000 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the sale, the director owned 10,419 shares of the company’s stock, valued at approximately $1,053,360.90. This trade represents a 16.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kyle Kline sold 3,594 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $363,353.40. The SEC filing for this sale provides additional information. Insiders sold a total of 35,594 shares of company stock worth $3,332,253 in the last 90 days. 18.51% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Globus Medical

Hedge funds have recently modified their holdings of the company. Invesco Ltd. grew its position in shares of Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after acquiring an additional 3,595,339 shares during the period. Burgundy Asset Management Ltd. raised its holdings in Globus Medical by 24.3% in the 2nd quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock worth $205,474,000 after purchasing an additional 679,691 shares during the period. Bank of Montreal Can boosted its position in Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after purchasing an additional 3,351,380 shares in the last quarter. William Blair Investment Management LLC boosted its position in Globus Medical by 17.2% during the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after purchasing an additional 414,134 shares in the last quarter. Finally, Sculptor Capital LP grew its holdings in Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after purchasing an additional 667,850 shares during the period. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.